Positive survival data from a randomized Phase II trial with PM1183 in platinum resistant ovarian cancer will be presented at ASCO

by Pharmamar Zeltia

​New clinical trial data from both Yondelis® and PM1183 have been selected by The American Society of Clinical Oncology (ASCO) for oral presentations

Read more

The pivotal and registrational trial of Yondelis® in Japan has been positive

by Pharmamar Zeltia

PharmaMar, a biotechnology subsidiary of Grupo Zeltia — MC:ZEL) has announced that its partner for Japan, Taiho Pharmaceutical Co., LTD., has communicated that the pivotal and registrational study o...

Read more
Subscribe to Directory
Write an Article

Recent News

Tuneable reverse photochromes in the sol...

A new technique allows the design of solid materia...

La Unidad de Chequeos de la Clínica sup...

El estudio realizado sobre una muestra significati...

Highlight

Interview with Dámaso Molero, general m...

by 3P Biopharmaceuticals

Dámaso Molero: “There are great opportunities in Latin America for ...

Neuroelectrics Raises $17.5M to Advance ...

by Neuroelectrics

​Neuroelectrics, a pioneer in brain stimulation technologies and the...

Photos Stream